濮阳东方看妇科技术非常哇塞(濮阳东方收费不高) (今日更新中)

White House aides drafted a fulsome statement for President Donald Trump on the death of Sen. John McCain, but it was never sent out, a person familiar with the matter confirmed to CNN.Several staff members believed the official White House statement, which went through an internal approval process, would be released at the time of the Arizona Republican's death, which occurred on Saturday. But as the President spent Sunday at his Virginia golf course, the statement never went out, the source said.White House aides did not make plans for a televised statement on McCain's passing, which would have been routine under similar circumstances in other recent presidencies.The Washington Post reported Sunday that Trump went against the advice of senior aides to issue an official White House statement praising McCain for his heroism and decades of service, telling aides he instead wanted to post a brief tweet.Trump's tweet Saturday night did not mention his military or Senate service or include any praise for the late Arizona Republican. 1052

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

When Sen. John McCain's family announced Friday that he was ending medical treatment?for aggressive brain cancer, the news shook Capitol Hill and prompted support from his Republican and Democratic colleagues alike. But one prominent voice was missing: President Donald Trump's.The White House press office did not react to the news, and when Trump traveled to Ohio in the evening he did not mention the ailing senator in a nearly hour-long speech to Ohio Republicans, which ran a gamut of topics from the death of Mollie Tibbetts to NFL protests to Kanye West.In past months, Trump has frequently referenced McCain's 2017 health care vote on the campaign trail without naming him, drawing the ire of the Arizona Republican's family."One of our wonderful senators said 'thumbs down' at 2 o'clock in the morning," the President said at a campaign event for New York's Rep. Claudia Tenney earlier this month.The senator's daughter, conservative commentator Meghan McCain, called Trump's comments "gross and pathetic" at the time.Although Trump claimed the Senate was one vote away, in reality the vote was only to go to conference with the House on the Senate's "skinny repeal" of Obamacare.The President did not repeat that reference, which has become a familiar refrain in his stump speech, on Friday evening.Trump also did not mention McCain at a signing ceremony earlier this month at Fort Drum, New York, for a defense spending bill the senator had spearheaded, the John S. McCain National Defense Authorization Act.Trump expressed support for McCain when the senator's tumor was first diagnosed."Senator John McCain has always been a fighter," the President said in a statement at the time. "Melania and I send our thoughts and prayers to Senator McCain, Cindy, and their entire family. Get well soon."A White House official said Trump also called McCain following word of the senator's diagnosis.And before that health care vote, the President called McCain an "American hero" in a tweet.Speaking to reporters on the South Lawn of the White House last December, Trump said he had talked with the senator's wife."I did speak to Cindy McCain, and I wished her well. I wished John well. They've headed back, but I understand he'll come if we ever needed his vote, which hopefully we won't. But the word is John will come back if we need his vote, and it's too bad," Trump said.He continued, "It's tough. He's going through a very, he's going through a very tough time. There's no question about it, but he will come back if we need his vote."The two have had a tortured relationship and McCain, who was diagnosed with glioblastoma, an aggressive form of brain cancer, in July 2017, has been one of the administration's most outspoken Republican critics.Trump has previously attacked McCain's record of service, saying the Vietnam veteran and one-time prisoner of war is "not a war hero" because he was captured."He is not a war hero," Trump told pollster Frank Luntz, who was hosting a July 2015 question-and-answer session at the Family Leadership Summit in Ames, Iowa."He is a war hero," Luntz interjected."He is a war hero because he was captured?" Trump said, cutting him off. "I like people that weren't captured, OK? I hate to tell you. He is a war hero because he was captured. OK, you can have -- I believe perhaps he is a war hero."Trump has since acknowledged that McCain is a hero, but he refused to apologize in subsequent interviews. 3511

While officials in Puerto Rico placed the official death toll from last year's Hurricane Maria at 64, researchers from Harvard believe the death toll was actually in the thousands. According to Harvard's study, there were an estimated 4,645 deaths directly or indirectly tied to the hurricane, which struck the island in September. Harvard estimated a mortality rate of 14.3 deaths per 1.000 people from September 20 through December 31, 2017 in Puerto Rico. Harvard said in its study that it believes its estimate is rather conservative due to a "survivor bias."Harvard conducted the study by performing a random survey of 3,299 households in Puerto Rico. "In our survey, interruption of medical care was the primary cause of sustained high mortality rates in the months after the hurricane, a finding consistent with the widely reported disruption of health systems," the study says. "Growing numbers of persons have chronic diseases and use sophisticated pharmaceutical and mechanical support that is dependent on electricity. Chronically ill patients are particularly vulnerable to disruptions in basic utilities, which highlights the need for these patients, their communities, and their providers to have contingency plans during and after disasters."Part of why there the death toll might have been underreported is due to how hurricane-related deaths are counted. In order to have a death counted as storm related, bodies had looked at by a medical examiner, which required a body to be transported to San Juan, or the medical examiner to travel to remote locations. With a lack of electricity and blocked roads, some bodies were likely buried before the government could count fatalities. Maria is considered the third-costliest hurricane in US history.  1816

WILMINGTON, Del. — President-elect Joe Biden’s son Hunter says he has learned from federal prosecutors that his tax affairs are under investigation. The investigation by the Delaware U.S. Attorney’s office was disclosed in a statement released Wednesday by President-elect Biden’s transition office and his son. "I take this matter very seriously but I am confident that a professional and objective review of these matters will demonstrate that I handled my affairs legally and appropriately, including with the benefit of professional tax advisors," the statement from Hunter Biden reads. The Biden-Harris transition team's statement reads, "President-elect Biden is deeply proud of his son, who has fought through difficult challenges, including the vicious personal attacks of recent months, only to emerge stronger."Hunter Biden has long been a target of President Donald Trump and his allies, who have accused him of profiting off his political connections. Trump and his supporters also raised unsubstantiated charges of corruption related to Hunter Biden’s work in Ukraine at the time his father was vice president.Hunter Biden's attorneys did not immediately return phone messages from the Associated Press seeking comment. 1240

来源：资阳报